(Q51365751)

4 April 2018

title

Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. (English)

1 reference

4 April 2018

1 reference

1 reference

1 reference

D Drover

1

1 reference

4 April 2018

H Lemmens

2

1 reference

4 April 2018

S Naidu

3

1 reference

4 April 2018

W Cevallos

4

1 reference

4 April 2018

M Darwish

5

1 reference

4 April 2018

D Stanski

6

1 reference

4 April 2018

publication date

1 December 2000

1 reference

4 April 2018

published in

Clinical Therapeutics

1 reference

4 April 2018

volume

22

1 reference

4 April 2018

issue

12

1 reference

4 April 2018

page(s)

1443-1461

1 reference

4 April 2018

Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983043-X

7 January 2021

Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983043-X

7 January 2021

The effects of single doses of CL284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983043-X

7 January 2021

Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983043-X

7 January 2021

Absorption rate, blood concentrations, and early response to oral chlordiazepoxide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983043-X

7 January 2021

A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983043-X

7 January 2021

Measuring the predictive performance of computer-controlled infusion pumps.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983043-X

7 January 2021

Estimating potency for the Emax-model without attaining maximal effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983043-X

7 January 2021

Zaleplon pharmacokinetics and absolute bioavailability

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983043-X

7 January 2021

EEG profile of intravenous zolpidem in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983043-X

7 January 2021

The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part I).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983043-X

7 January 2021

Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983043-X

7 January 2021

Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983043-X

7 January 2021

10.1016/S0149-2918(00)83043-X

Identifiers

DOI

1 reference

4 April 2018

1 reference

4 April 2018